Aurora Cannabis recent approval from Health Canada will allow the company, in partnership with Capcium Inc., to immediately proceed with production of softgel capsules at its facility in Pointe-Claire, Québec.
Aurora owns 20 per cent of Montreal-based Capcium, its exclusive manufacturer of cannabis softgel products in North America.
“Aurora continues to deliver on its strategy to build a robust portfolio of higher-margin products,” said Aurora CEO Terry Booth.
“While many people continue to use dried buds for medical symptom relief, there is growing global demand for alternative drug delivery technologies.”
According to the company, Cannabis capsules are preferred by healthcare professionals, as they offer discreet, precision dosage and have consistent, predictable efficacy.